1ZL Stock Overview Develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Zai Lab Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Zai Lab Historical stock prices Current Share Price US$28.00 52 Week High US$31.80 52 Week Low US$12.40 Beta 1.02 1 Month Change 14.75% 3 Month Change 9.38% 1 Year Change 50.54% 3 Year Change -45.10% 5 Year Change -51.30% Change since IPO 16.95%
Recent News & Updates
Zai Lab Limited to Report Q4, 2024 Results on Feb 27, 2025 Jan 28
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer Jan 23
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia Jan 17
Zai Lab Limited Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv301 Trial in Patients with Recurrent or Metastatic Cervical Cancer Jan 15
Zai Lab Limited Announces Resignation of Kai-Xian Chen as Independent Non-Executive Director Jan 02
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03 See more updates
Zai Lab Limited to Report Q4, 2024 Results on Feb 27, 2025 Jan 28
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer Jan 23
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia Jan 17
Zai Lab Limited Announces Positive Topline Results for Tivdak in the China Subpopulation of the Global Phase 3 Innovatv301 Trial in Patients with Recurrent or Metastatic Cervical Cancer Jan 15
Zai Lab Limited Announces Resignation of Kai-Xian Chen as Independent Non-Executive Director Jan 02
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer Dec 03
Zai Lab Limited Announces the Inclusion of Augtyro (Repotrectinib) for Ros1+ Nsclc and Other Updates in China’S National Reimbursement Drug List Nov 28 Zai Lab Limited has completed a Follow-on Equity Offering in the amount of $199.999994 million. Nov 16
Zai Lab Limited has filed a Follow-on Equity Offering in the amount of $200 million. Nov 15
Third quarter 2024 earnings released: US$0.42 loss per share (vs US$0.71 loss in 3Q 2023) Nov 14
Zai Lab Limited and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China Nov 12
Zai Lab Limited Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China Oct 29
Zai Lab Limited Presents Data from the Ongoing Global Phase 1A/1B Study of ZL-1310 Oct 26
Zai Lab Limited to Report Q3, 2024 Results on Nov 12, 2024 Oct 16
Zai Lab Limited to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024 Oct 09
Zai Lab Limited to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 Sep 18
Second quarter 2024 earnings released: US$0.82 loss per share (vs US$1.25 loss in 2Q 2023) Aug 07 Zai Lab and argenx Announces Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China Jul 16
Zai Lab Limited to Report Q2, 2024 Results on Aug 06, 2024 Jul 11
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024 Jun 13 Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
Zai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China May 15
Zai Lab Limited Announces Approval of AUGTYRO (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPA May 14
First quarter 2024 earnings released: US$0.55 loss per share (vs US$0.51 loss in 1Q 2023) May 09
Forecast to breakeven in 2026 Apr 18
Zai Lab Limited to Report Q1, 2024 Results on May 08, 2024 Apr 16
Zai Lab Limited, Annual General Meeting, Jun 18, 2024 Mar 29
Zai Lab Partner Novocure Announces Metis Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating A Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer Mar 27
Zai Lab Limited to Report Fiscal Year 2023 Results on Mar 27, 2024 Mar 19
Zai Lab Limited to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors Mar 15
Full year 2023 earnings released: US$3.46 loss per share (vs US$4.63 loss in FY 2022) Feb 28
Zai Lab Limited to Report Fiscal Year 2023 Results on Feb 27, 2024 Jan 26
Zai Lab Announces the New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC Jan 11
Zai Lab Limited Announces the First Listing of VYVGART(R) (efgartigimod alfa injection) and Other Updates in China's National Reimbursement Drug List Dec 13
Third quarter 2023 earnings released: US$0.71 loss per share (vs US$1.68 loss in 3Q 2022) Nov 08
New major risk - Share price stability Nov 07
Zai Lab Limited to Report Q3, 2023 Results on Nov 07, 2023 Oct 19
Zai Lab Limited Announces Breakthrough Therapy Designation Granted for Repotrectinib for Treatment of Patients with Ntrk-Positive Tki-Pretreated Advanced Solid Tumors in China Aug 31
New minor risk - Shareholder dilution Aug 09
Second quarter 2023 earnings released: US$1.25 loss per share (vs US$1.44 loss in 2Q 2022) Aug 08
Zai Lab Limited to Report Q2, 2023 Results on Aug 07, 2023 Jul 23 Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Jul 17
Zai Lab Announces Acceptance by China’s NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis Jul 12
New minor risk - Profitability Jul 07
Zai Lab Limited Announces Chief Financial Officer Changes, Effective July 7, 2023 Jul 07 Zai Lab Limited and argenx Announce Approval of VYVGART (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies Jun 07
Zai Lab Limited to Highlight New Data from its Oncology Pipeline at 2023 ASCO Annual Meeting Jun 02
Zai Lab Limited Announces China’s National Medical Products Administration Grants Priority Review to Repotrectinib May 19
First quarter 2023 earnings released: US$0.51 loss per share (vs US$0.86 loss in 1Q 2022) May 10
Forecast to breakeven in 2025 Mar 17
Full year 2022 earnings released: US$4.62 loss per share (vs US$7.58 loss in FY 2021) Mar 03
Zai Lab Limited to Report Fiscal Year 2022 Results on Mar 01, 2023 Feb 10
Zai Lab Limited Announces New Drug Application for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s National Medical Products Administration Jan 31 Zai Lab Limited Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Zai Lab Limited Appoints Michel Vounatsos to the Board of Directors Jan 10
Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint Jan 06
Zai Lab Limited Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development Jan 04
Zai Lab Limited Presents Interim Overall Survival Data for ZEJULA® (niraparib) from the NORA Phase 3 Study at the ESMO Virtual Plenary Dec 16
Independent Director recently sold €263k worth of stock Dec 10
Third quarter 2022 earnings released Nov 11
Zai Lab Limited Announces the Appointment of Peter Huang as Chief Scientific Officer Nov 09
Zai Lab Limited to Report Q3, 2022 Results on Nov 09, 2022 Oct 19
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting Sep 21
Second quarter 2022 earnings released: US$1.44 loss per share (vs US$1.76 loss in 2Q 2021) Aug 11
Zai Lab Limited Appoints Joshua Smiley as Chief Operating Officer Aug 04
Zai Lab Limited to Report Q2, 2022 Results on Aug 09, 2022 Jul 20
China’s National Medical Products Administration Accepts Biologics License Application of Zai Lab Limited Jul 14
Zai Lab Limited Announces Breakthrough Therapy Designations Granted for Repotrectinib in China Jun 11
Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer Jun 04
First quarter 2022 earnings released: US$0.86 loss per share (vs US$2.64 loss in 1Q 2021) May 11
Zai Lab Limited, Annual General Meeting, Jun 22, 2022 May 03
No longer forecast to breakeven Apr 27 Shareholder Returns 1ZL DE Biotechs DE Market 7D 6.1% -3.2% 2.7% 1Y 50.5% -7.9% 17.0%
See full shareholder returns
Return vs Market: 1ZL exceeded the German Market which returned 17% over the past year.
Price Volatility Is 1ZL's price volatile compared to industry and market? 1ZL volatility 1ZL Average Weekly Movement 7.4% Biotechs Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.1% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: 1ZL's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1ZL's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients.
Show more Zai Lab Limited Fundamentals Summary How do Zai Lab's earnings and revenue compare to its market cap? 1ZL fundamental statistics Market cap €3.01b Earnings (TTM ) -€258.12m Revenue (TTM ) €339.03m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1ZL income statement (TTM ) Revenue US$355.75m Cost of Revenue US$395.21m Gross Profit -US$39.46m Other Expenses US$231.39m Earnings -US$270.85m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
Earnings per share (EPS) -2.49 Gross Margin -11.09% Net Profit Margin -76.13% Debt/Equity Ratio 16.9%
How did 1ZL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/16 23:51 End of Day Share Price 2025/02/14 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Zai Lab Limited is covered by 29 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Michael Meng BOCI Research Ltd. Wai Chak Yuen BOCI Research Ltd. Linda Lu BOCI Research Ltd.
Show 26 more analysts 
